Treatment-resistant depression. Part II: Psychopharmacological treatment, strategies,brain stimulation and other somatic treatmentoptions;Therapieresistente Depressionen. Teil II: Psychopharmakologische Behandlungsstrategien, Hirnstimulations- und andere somatische Therapieverfahren

Fortschritte der Neurologie Psychiatrie

Volumn 78, Issue 3, 2010, Pages 169-183

  Schmauss M ^a   Messer, T ^a  

^a Bezirkskrankenhaus Augsburg   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

AMFEBUTAMONE; AMPHETAMINE; ANTICONVULSIVE AGENT; ANTIDEPRESSANT AGENT; BUSPIRONE; CITALOPRAM; CLOMIPRAMINE; CLONIDINE; DESIPRAMINE; DEXAMPHETAMINE; ESTROGEN; FLUOXETINE; FLUVOXAMINE; LIOTHYRONINE; LITHIUM CARBONATE; METHYLPHENIDATE; MIANSERIN; MIRTAZAPINE; MOCLOBEMIDE; MONOAMINE OXIDASE INHIBITOR; PAROXETINE; REBOXETINE; SEROTONIN NORADRENALIN REUPTAKE INHIBITOR; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; TETRACYCLIC ANTIDEPRESSANT AGENT; TRANYLCYPROMINE; TRICYCLIC ANTIDEPRESSANT AGENT; UNINDEXED DRUG; VENLAFAXINE; LITHIUM DERIVATIVE; NEUROLEPTIC AGENT;

BRAIN DEPTH STIMULATION; CLINICAL TRIAL; DEPRESSION; DRUG COMBINATION; DRUG EFFECT; DRUG MEGADOSE; DRUG POTENTIATION; DRUG SUBSTITUTION; DRUG WITHDRAWAL; HUMAN; HYPOTHERMIA; MAJOR DEPRESSION; MONOTHERAPY; PHOTOTHERAPY; PSYCHOPHARMACOLOGY; PSYCHOPHARMACOTHERAPY; REVIEW; SEXUAL DYSFUNCTION; TRANSCRANIAL MAGNETIC STIMULATION; VAGUS NERVE STIMULATION; DRUG RESISTANCE; ELECTROSTIMULATION THERAPY; MULTIMODALITY CANCER THERAPY;

ANTIDEPRESSIVE AGENTS; ANTIPSYCHOTIC AGENTS; COMBINED MODALITY THERAPY; DEPRESSIVE DISORDER; DRUG RESISTANCE; ELECTRIC STIMULATION THERAPY; ESTROGENS; HUMANS; LITHIUM COMPOUNDS; PHOTOTHERAPY; TRANSCRANIAL MAGNETIC STIMULATION; TRIIODOTHYRONINE;

EID: 77949308008     PISSN: 07204299     EISSN: 14393522     Source Type: Journal    
DOI: 10.1055/s-0028-1109692     Document Type: Review

References (83)

1. Möller H J. Therapieresistenz auf Antidepressiva. Nervenarzt 2004 75 499-517
2. Möller H J. Medikamentöse Therapiestrategien bei therapieresistenter unipolarer Depression. Psychopharmakotherapie 2004 11 34-41
3. Souery D, Papakostas G I., Trivedi M H. Treatment-resistant depression. JClin Psychiatry 2006 67 (Suppl 6) 16-22
4. Adli M, Baethge C, Heinz A et al. Is dose escalation of antidepressants a rational strategy after a medium-dose treatment has failed? A systematic review. Eur Arch Psychiatry Clin Neurosci 2005 255 387-400
5. Harrison C L., Ferrier N, Young A H. Tolerability of high-dose venlafaxine in depressed patients. JPsychopharmacol 2004 18 200-204
6. Thase M E., Shelton R C., Khan A. Treatment with venlafaxine extended release after SSRI nonresponse or intolerance: a randomized comparison of standard- and higher-dosing strategies. JClin Psychopharmacol 2006 26 250-258
7. Thase M E., Rush A J. When at first you dont succeed: sequential strategies for antidepressant nonresponsers. JClin Psychiatry 1997 58 (Suppl 1) 23-29
8. Thase M E., Feighner J P., Lydiard R B. Citalopram treatment of fluoxetine nonresponders. JClin Psychiatry 2001 62 683-687
9. Fava M, McGrath P J., Sheu W P. et al. Switching fluoxetine to reboxetine: an efficacy and safety study in depressed patients resistant to fluoxetine (abstract p03.198). Int J Neuropsychopharmacol 2000 3 234
10. Thase M E., Rush A J. Treatment-resistant depression. Bloom FE, Kupfer DJ Psychopharmacology: the fourth generation of progress New York Raven Press 1995 1081-1097
11. AHCPR. Depression Guidelines Panel-Depression in primary care: Clinical practice guideline no. 5 AHCPR pub No 93 0550,. Rockville MD 1993
12. Rush A J., Trivedi M H., Wisniewski S R. et al. Bupropion-SR, sertraline, or venlafaxine-XR after failure of SSRIs for depression. N Engl J Med 2006 354 1231-1242
13. Taylor D, Stewart S, Connolly A. Antidepressant withdrawal symptoms-telephone calls to a national medication helpline. JAffect Disord 2006 95 129-133
14. Dodd S, Horgan D, Malhi G et al. To combine or not to combine? A literature review of antidepressant combination therapy. JAffect Disord 2005 89 1-11
15. Schmauß M, Messer T. Kombination von Antidepressiva eine sinnvolle Behandlungsstrategie bei therapieresistenten Depressionen? Fortschr Neurol Psychiat 2009 77 316-325
16. Schmauß M, Messer T. Polypharmazie in der Behandlung depressiver Störungen. Messer T, Schmauß M Polypharmazie in der Behandlung psychischer Erkrankungen Wien, New York Springer 2009; im Druck 2. Aufl
17. Bauer M, Linden M. Die Kombination verschiedener Antidepressiva in der Behandlung therapieresistenter Depressionen. Nervenarzt 1993 64 343-347
18. Frye M A., Ketter T A., Leverich G S. et al. The increasing use of polypharmacotherapy for refractory mood disorders: 22 years of study. JClin Psychiatry 2000 61 9-15
19. Murphy D L., Sunderland T, Cohen R M. Monoamine oxidase-inhibiting antidepressants a clinical update. Psychiatr Clin North Am 1984 7 549-562
20. Schuckit M, Robins E, Feighner J. Tricyclic antidepressants and monoamine oxidase inhibitors. Arch Gen Psychiatry 1971 24 509-514
21. Schmauß M. Kombinationstherapie nicht-selektiver Monoamin-Rückaufnahme-Inhibitoren mit MAO-Hemmern. Riederer P, Laux G, Pöldinger W Neuro-Psychopharmaka. Bd 3: Antidepressiva Phasenprophylaktika und Stimmungsstabilisierer, Wien, New York 2002 2. Aufl 551-557
22. Steinberg R, Jost C, Weess H G. et al. Combination of tricyclic antidepressants with moclobemide or tranylcypromine outcome data in therapy resistant MD. Neuropsychopharmacology (Suppl) 1994 10 62
23. Koenig F, Wolfersdorf M. Combination therapy using moclobemide with tricyclic and tetracyclic antidepressants to treat therapy-resistant depression. Pharmacopsychiatry 1997 30 93-96
24. Neuvonen P, Pohjola-Sintonen S, Tacke U et al. Five fatal cases of serotonin syndrome after moclobemide-citalopram or moclobemide-clomipramine overdoses. Lancet 1993 342 1419
25. Hawley C J., Quick S J., Ratnam S. Safety and tolerability of combined treatment with moclobemide and SSRI: a systematic study of 50 patients. Int Clin Psychopharmacol 1996 11 187-191
26. Dams R, Benijts T H., Lambert W E. et al. A fatal case of serotonin syndrome after combined moclobemide-citalopram intoxication. JAnal Toxicol 2001 25 147-151
27. Volz H P., Gleiter C H., Möller H J. Monoaminoxidasehemmer in der Psychiatrie. Nervenarzt 1996 67 339-347
28. Baron B M., Ogden A, Seigel B W. et al. Rapid down regulation of -adrenoreceptors by co-administration of desipramine and fluoxetine. Eur J Pharmacol 1988 154 125-134
29. Nelson J C. Augmentation strategies with serotonin-noradrenergic combinations. JClin Psychiatry 1998 59 65-68
30. Nelson J C., Mazure C M., Browers M BJ et al. A preliminary, open study of the combination of fluoxetine and desipramine for rapid treatment of major depression. Arch Gen Psychiatry 1991 48 303-307
31. Dam J, Ryde L, Svejso J et al. Morning fluoxetine plus evening mianserin versus morning fluoxetine plus evening placebo in the acute treatment of major depression. Pharmacopsychiatry 1998 31 48-54
32. Ferreri M, Lavergne F, Berlin I et al. Benefits from mianserin augmentation of fluoxetine in patients with major depression non-responders to fluoxetine alone. Acta Psychiatr Scand 2001 103 66-72
33. Maes M, Vandoolaeghe E, Desnyder R. Efficacy of treatment with trazodone in combination with pindolol or fluoxetine in major depression. JAffect Disord 1996 41 201-210
34. Harkin A, Kelly J P., McNamara M et al. Activity and onset of action of reboxetine and effect of combination with sertraline in an animal model of depression. Eur J Pharmacol 1999 364 123-132
35. Carpenter L L., Yasmin S, Price H. A double-blind, placebo-controlled study of antidepressant augmentation with mirtazapine. Biol Psychiatry 2002 51 183-188
36. Debonnel G, Gobbi G, Turcotte J et al. The alpha-2 antagonist mirtazapine combined with the SSRI paroxetine induces a greater antidepressant response: a double-blind controlled study. Presented at the 39th ACNP Meeting, Dec 10 14, San Juan, Puerto Rico, 2002.
37. Farah A. Relief of SSRI-induced sexual dysfunction with mirtazapine treatment (letter). JClin Psychiatry 1999 60 260-261
38. McGrath P J., Stewart J W., Fava M et al. Tranylcypromine versus venlafaxine plus mirtazapine following three failed antidepressant medication trials for depression: a Star*D report. Am J Psychiatry 2006 163 1531-1541
39. Lam R W., Hossie H, Solomons K et al. Citalopram and bupropion SR: combining vs. switching in patients with treatment-resistant depression. JClin Psychiatry 2004 65 337-340
40. Papakostas G I., Worthington J J., Iosifescu D V. et al. The combination of duloxetine and bupropion for treatment-resistant major depressive disorder. Depress Anxiety 2006 3 178-181
41. DeBattista C, Solvason H B., Poirier J et al. A prospective trial of bupropion SR augmentation of partial and non-responsers to serotonergic antidepressants. JClin Psychopharmacol 2003 23 27-30
42. Zisook S, Rush A J., Haight B R. et al. Use of bupropion in combination with serotonin reuptake inhibitors. Biol Psychiatry 2006 59 203-210
43. Trivedi M H., Fava M, Wisniewski S R. et al. Medication augmentation after the failure of SSRIs for depression. N Engl J Med 2006 12 1243-1252
44. Lam R W., Wan D D., Cohen N L. et al. Combining antidepressants for treatment-resistant depression. A review. JClin Psychiatry 2002 63 685-693
45. Bauer M, Whybrow P C. Thyroid hormone, neural tissue and mood modulation. World J Biol Psychiatry 2001 2 57-67
46. Baumgartner A. Schilddrüsenhormone und depressive Erkrankungen. Teil I. Nervenarzt 1993 64 1-10
47. Crossley N A., Bauer M. Acceleration and augmentation of antidepressants with lithium for depressive disorders: two meta-analysis of randomized, placebo-controlled trials. JClin Psychiatry 2007 68 935-940
48. Bauer M, Forsthoff A, Baethge C et al. Lithium augmentation therapy in refractory depression update 2002. Eur Arch Psychiatry Clin Neurosci 2003 253 132-139
49. Zullino D, Baumann P. Lithium augmentation in depressive patients not responding to selective serotonin reuptake inhibitors. Pharmacopsychiatry 2001 34 119-127
50. Shelton R C., Papakostas G I. Augmentation of antidepressants with atypical antipsychotics for treatment-resistant major depressive disorder. Acta Psychiatr Scand 2008 117 253-259
51. Shelton R C., Williamson D J., Corya S A. et al. Olanzapine/fluoxetine combination for treatment-resistant depression: a controlled study of SSRI and nortriptyline resistance. JClin Psychiatry 2005 66 1289-1297
52. Corya S A., Williamson D, Sanger T M. et al. A randomized, double-blind comparison of olanzapine/fluoxetine combination, olanzapine, fluoxetine, and venlafaxine in treatment-resistant depression. Depression and Anxiety 2006 23 364-372
53. Papakostas G I., Shelton R C., Smith J et al. Augmentation of antidepressants with atypical antipsychotic medications for treatment-resistant major depressive disorder: a meta-analysis. JClin Psychiatry 2007 68 826-831
54. Warneke L. Psychostimulants in psychiatry. Can J Psychiatry 1990 35 3-10
55. Robertson P Jr, Hellriegel E T. Clinical pharmacokinetic profile of modafinil. Clin Pharmacokinet 2003 42 123-137
56. Ninan P T., Hassman H A., Glass S J. et al. Adjunctive modafinil at initiation of treatment with a selective serotonin reuptake inhibitor enhances the degree and onset of therapeutic effects in patients with major depressive disorder and fatigue. JClin Psychiatry 2004 65 414-420
57. Landen M, Bjorling G, Agren H et al. A randomized, double-blind, placebocontrolled trial of buspirone in combination with an SSRI in patients with treatment refractory depression. JClin Psychiatry 1998 59 664-668
58. Sachs G, Collins M A., Altshuler L et al. Divalproax sodium versus placebo for the treatment of bipolar depression. APA 2002 Syllabus & Proceedings Summary Washington DC 2002
59. Barbee J G., Jamhour N J. Lamotrigine as an augmentation agent in treatment-resistant depression. JClin Psychiatry 2002 63 (Suppl 8) 737-741
60. Dietrich D E., Emrich H M. The use of anticonvulsants to augment antidepressant medication. JClin Psychiatry 1998 59 (Suppl 5) 51-58
61. Cassano P, Lattanzi L, Fava M et al. Ropinirole in treatment-resistant depression: a 16-week pilot study. Can J Psychiatry 2005 50 357-360
62. Dawson L A., Nguyen H Q. The role of 5-HAT(1A) and 5-HAT(1B/ 1D) receptors on the modulation of acute fluoxetine-induced changes in extracellular 5-HAT: the mechanism of action of (+ /-) pindolol. Neuropharmacology 2000 39 1044-1052
63. Olver J S., Cryan J F., Burrows G D. et al. Pindolol augmentation of antidepressants: a review and rationale. Aust N Z J Psychiatry 2000 34 71-79
64. Erfurth A, Möller H J. Vorgehen bei Antidepressiva-Nonrespondern. Möller HJ Therapie psychiatrischer Erkrankungen Stuttgart, New York Thieme 2000 2. Aufl 407-412
65. Abrams R. Electroconvulsive Therapy. Oxford, New York Oxford University Press 2002
66. Pagnin D, Queiroz V de, Pini S et al. Efficacy of ECT in depression: a meta-analytic review. JECT 2004 20 13-20
67. American Psychiatric Association (APA). Practice guideline for the treatment of patients with major depressive disorder (revision). Am J Psychiatry 2000 157 1-45
68. National Institute for Clinical Excellence. Depression: Management of depression in primary and secondary care. Clinical Guidelines 2004 23 http://www.nice.org.uk/CGO23 NICEguideline
69. UK ECT Review-Group. Efficacy and safety of electroconvulsive therapy in depressive disorders: a systematic review and meta-analysis. Lancet 2003 361 799-808
70. Bourgon L N., Kellner C H. Relapse of depression after ECT: a review. JECT 2000 16 19-31
71. OReardon J P., Solvason H B., Janicak P G. et al. Efficacy and safety of transcranial magnetic stimulation in the acute treatment of major depression: a multisite randomized controlled trial. Biol Psychiatry 2007 62 1208-1216
72. Rush A J., George M S., Sackeim H A. et al. Vagus nerve stimulation (VNS) for treatment-resistant depressions: a multicenter study. Biol Psychiatry 2000 47 276-286
73. Kuhn J, Huff W, Lee S H. et al. Tiefenhirnstimulation bei psychiatrischen Erkrankungen. Fortschr Neurol Psychiat 2007 75 447-457
74. Golden R N., Gaynes B N., Ekstrom R D. et al. The efficacy of light therapy in the treatment of mood disorders. A review and meta-analysis of the evidence. Am J Psychiatry 2005 62 656-662
75. Kennedy S H., Lam R W., Cohen N L. et al. Clinical guidelines for the treatment of depressive disorders. IV: Medications and other biological treatments. Can J Psychiatry 2001 46 38-58
76. Rush A J. Aktueller Stand und Perspektiven der Forschung. Bauer M, Berghöfer A, Adli M Akute und therapieresistente Depressionen Heidelberg Springer 2005 2. Aufl 3-19
77. Adli M, Rush A J., Möller H J. Algorithms for optimizing the treatment of depression: making the right decision at the right time. Pharmacopsychiatry 2003 36 222-229
78. Adli M, Bauer M, Rush A J. Algorithms and collaborative-care systems for depression: are they effective and why? A systematic review. Biol Psychiatry 2006 59 1029-1038
79. Trivedi M H., Rush A J., Crismon M L. et al. Texas Medication Algorithm Project (TMAP): Clinical results for patients with major depressive disorder. Arch Gen Psychiatry 2004 61 669-680
80. DGPPN. S3-Leitlinie zur Behandlung depressiver Störungen. Darmstadt Steinkopff 2009; im Druck
81. Canadian Psychiatric Association. Clinical guidelines for the treatment of depressive disorders. Can J Psychiatry 2001 46 (Suppl 1) 13-90
82. Menke R, Gaebel W. Leitlinienkonformitt in Klinik und Praxis. Psychopharmakotherapie 2005 12 (Suppl 13) 3-7
83. Bauer M, Whybrow P C., Angst J et al. Biologische Behandlung unipolarer depressiver Störungen, Behandlungsleitlinien der World Federation of Societies of Biological Psychiatry (WFSBP). Stuttgart Wissenschaftliche Verlagsgesellschaft 2004